Seattle Genetics Upgraded To Overweight From Equal Weight At Barclays By: TalkMarkets October 20, 2017 at 09:02 AM EDT Barclays analyst Geoff Meacham upgraded Seattle Genetics to Overweight and raised his price target for the shares to $70 from $60. Read More >> Related Stocks: Regeneron Pharmaceuticals Seagen Inc